Friday May 3 | Seeking Alpha
Ampio Pharma Initiates Phase III, Investors Extend Momentum
Shares of Ampio Pharmaceuticals are on a roll after the company reported on April 24th that it completed enrollment for its Phase III run-in trial with Ampion, a naturally occurring anti-inflammatory compound that is under development for the treatment of osteoarthritis of the knee.
Top three most dangerous pain medications
Pain medications and the adverse drug reactions to them are the fourth leading cause of death in the US.
Some Pain Drugs Increase the Risk of Heart Attack
ROCHESTER, Minn. - Some of the most common pain drugs used by older adults who experience discomfort in muscles and joints can increase the risk of heart attack and stroke.
Pfizer Inc.'s Celebrex Meets Goals in Juvenile Rheumatoid Arthritis Study
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK-- -- Pfizer Inc.
Inflavestin, a new weapon in the battle against osteoarthritis pain.
In a recent clinical trial, 60 subjects aged between 40 and 75 with moderate to severe osteoarthritis of the hip and knee were administered Inflavestin, a proprietary blend of Scutellaria biacalensis and Acacia catechu.